Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMH7OIA)

• Drug Name: Infliximab Drug Info
• Synonyms: Remicade (TN)

Indication

Disease Entry	ICD 11	Status	REF
Crohn disease	DD70	Approved	[1]
Lupus nephritis	4A40.0Y	Approved	[2]
Plaque psoriasis	EA90.0	Approved	[3]
Psoriatic arthritis	FA21	Approved	[4]
Toxic epidermal necrolysis		Approved	[5]
Ulcerative colitis	DD71	Approved	[6]
Asthma	CA23	Phase 3	[3]
Rheumatoid arthritis	FA20	Phase 2	[7]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Investigative	[8]

• Therapeutic Class: Immunosuppressive Agents
• Cross-matching ID:
  TTD Drug ID: DMH7OIA
  VARIDT Drug ID: DR00451

Molecule-Related Drug Atlas

Drug(s) Targeting Tumor necrosis factor (TNF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[10]
Nafamostat	DMU1XOD	Pancreatitis	DC31-DC34	Approved	[11]
Pentoxifylline	DMU3DNC	Alcoholic hepatitis	DB94.1	Approved	[12]
Lenalidomide	DM6Q7U4	Adult T-cell leukemia/lymphoma		Approved	[13]
Enbrel	DM7RNP3	Arthritis	FA20	Approved	[14]
Golimumab	DMHZV7X	Psoriatic arthritis	FA21	Approved	[15]
Certolizumab	DM5CL9Z	Rheumatoid arthritis	FA20	Approved	[16]
Etanercept	DMCV109	Arthritis	FA20	Approved	[17]
Adalimumab	DMQMV1B	Crohn disease	DD70	Approved	[18]
Golnerminogene pradenovac	DMKWV4B	Esophageal cancer	2B70	Phase 3	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tumor necrosis factor (TNF)	TTF8CQI	TNFA_HUMAN	Not Available	[9]

References

• [1] Management of inflammatory bowel disease. Med J Aust. 2018 Sep 1;209(7):318-323.
• [2] Infliximab biosimilar-induced lupus nephritis: A case report. Mod Rheumatol Case Rep. 2023 Dec 29;8(1):74-76.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5004).
• [4] Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. RMD Open. 2020 Feb;6(1):e001117.
• [5] Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome. Cochrane Database Syst Rev. 2022 Mar 11;3(3):CD013130.
• [6] Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 8;353(23):2462-76.
• [7] ClinicalTrials.gov (NCT00029042) Infliximab to Treat Children With Juvenile Rheumatoid Arthritis
• [8] Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020 May 2;395(10234):1407-1409.
• [9] Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9.
• [10] Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1312-5.
• [11] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [12] Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol. 2004 Apr;41(2 Suppl 4):13-20.
• [13] Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351.
• [14] Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loose... J Bone Joint Surg Am. 2001 Jul;83(7):1057-61.
• [15] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [16] Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
• [17] The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
• [18] Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7.
• [19] TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience... Ann Surg Oncol. 2005 Oct;12(10):825-30.